CCNB1 and prostate carcinoma: In this study, cyclin B1 appeared to be the most reactive antigen in prostate cancer and an analysis was performed to determine whether a subset and not necessarily all the 15 TAAs (Table 1) was sufficient to achieve optimal antibody frequency.